Risks
4 risks
Risk Intelligence
PenG MIP impact on gross margins
View Risks →Alkem Laboratories Limited — Q3 FY26
Alkem Laboratories reported Q3 FY26 revenue of ₹3,737 crore (+10.7% YoY) and EBITDA of ₹828 crore (+9% YoY), with EBITDA margin at 22.2%.
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Alkem Laboratories reported Q3 FY26 revenue of ₹3,737 crore (+10.7% YoY) and EBITDA of ₹828 crore (+9% YoY), with EBITDA margin at 22.2%. Domestic business grew 5.5% (10%+ on a billing-to-billing basis), while international sales surged 26.6% to ₹1,216 crore. The company announced a 55% acquisition of Occlutech, a structural heart device company, for ~₹1,100 crore, targeting 25% EBITDA margins in 3-5 years. Management remains bullish on domestic growth, expecting 100-150 bps above IPM, and guided for 14% CAGR in Occlutech's revenue. Key risks include the impact of PenG MIP (₹80-100 crore estimated) and execution challenges in Medtech integration.
एल्केम लैबोरेटरीज ने तीसरी तिमाही में 3,737 करोड़ रुपये की कमाई की, जो पिछले साल से 10.7% ज्यादा है। कंपनी का मुनाफा (EBITDA) 828 करोड़ रुपये रहा, जो 9% बढ़ा है। भारत में बिक्री 5.5% बढ़ी, जबकि विदेशों में 26.6% की तेज उछाल आई और यह 1,216 करोड़ रुपये पहुंच गई। कंपनी ने दिल के इलाज में काम आने वाली कंपनी ऑक्लूटेक का 55% हिस्सा करीब 1,100 करोड़ रुपये में खरीदा है। उम्मीद है कि 3-5 साल में इसका मुनाफा 25% तक पहुंच जाएगा। कंपनी को भारत में बिक्री बढ़ने की उम्मीद है, लेकिन कुछ जोखिम भी हैं, जैसे दवा की कीमतों पर सरकारी नियंत्रण का असर और नए कारोबार को सफल बनाने की चुनौती।
Risks4 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Domestic business YTD growth
10%
+10% YoY
Domestic business grew ~10% YTD, with prescription business growing at 11-12%.
International sales growth
₹1,216 crore
+26.6% YoY
International sales grew 26.6% YoY to ₹1,216 crore in Q3.
Occlutech revenue guidance (CY26)
₹600 crore
N/A
Occlutech expected to generate ~₹600 crore revenue in calendar year 2026.
Occlutech EBITDA margin target (3 years)
23-24%
+19-20pp
Occlutech EBITDA margin expected to improve from ~4% to 23-24% in 3 years.
What Changed vs Last Quarter
NEW
Occlutech revenue CAGR of 14% over 5 years
Occlutech is expected to grow at a 14% CAGR over the next five years from existing products, excluding new product launches.
NEW
Occlutech EBITDA margin of 23-24% in 3 years
Occlutech's EBITDA margin is expected to reach 23-24% within three years, up from current ~4%.
NEW
Alkem Medtech EBITDA margin of 25% in 4-5 years
Alkem Medtech (including Occlutech) is expected to achieve 25% EBITDA margin in 4-5 years.
UPDATED
Domestic business to grow 100-150 bps above IPM
Management expects domestic business to continue growing 100-150 basis points above the Indian pharmaceutical market growth rate.
DROPPED
US business to deliver low double-digit growth in FY26
US growth expected to be ~10-11% for FY26, driven by new launches including Sacubitril/Valsartan.
DROPPED
Full-year EBITDA margin guidance of 19.5-20%
Despite H2 headwinds from US CDMO OpEx and GST impact, management expects FY26 EBITDA margin of 19.5-20%.
DROPPED
US CDMO plant to reach INR 300 crore annual run rate in 12-18 months
The US CDMO plant is expected to achieve an annual revenue run rate of INR 300 crore within 12-18 months of operations.
NEW RISK
PenG MIP impact on gross margins
The minimum import price on PenG and its derivatives could impact gross margins by ₹80-100 crore, partially offset by pricing actions in trade generics.
NEW RISK
Execution risk in Medtech integration
The Occlutech acquisition involves integrating a global Medtech company with different business dynamics, posing execution challenges.
NEW RISK
Trade generic business headwinds
The trade generic business has been flattish this year due to competitive pressures, and recovery to high single-digit growth may take time.
NEW RISK
Denosumab U.S. entry delayed by litigation
U.S. entry for denosumab biosimilars is delayed to end-2026 due to ongoing litigation with Amgen.
RISK GONE
Price erosion in Sacubitril/Valsartan
The key US launch faces competitive pressure; price erosion could impact US growth trajectory in coming quarters.
RISK GONE
GST impact on profitability
Loss of Sikkim facility benefit will result in INR 50-60 crore impact in H2, pressuring margins.
RISK GONE
US CDMO plant ramp-up risk
New US CDMO plant will incur ~INR 50 crore quarterly OpEx with only ~INR 20 crore revenue initially, delaying breakeven.
RISK GONE
Penicillin G MIP uncertainty
Potential government MIP on penicillin G could increase costs; management declined to comment as it is speculative.
🤫 Topics management stopped discussing
Mentioned in Q1 FY25, Q2 FY26, Q3 FY25
Despite H2 headwinds from US CDMO OpEx and GST impact, management expects FY26 EBITDA margin of 19.5-20%.
Mentioned in Q1 FY26, Q4 FY25
Capital expenditure for FY26 is guided at INR 750 crore, primarily for CDMO and biosimilar facilities.
Mentioned in Q1 FY25, Q3 FY25
Q4 implied growth of ~9.5-10% driven by strong secondary optics and low base.
Mentioned in Q2 FY25, Q4 FY25
Management expects EBITDA margins to remain stable at around 19.5% in FY26, supported by operating leverage and despite higher R&D investments.
Mentioned in Q2 FY25, Q3 FY25
Price erosion in US generics is ~5% (2.5% on NRV basis) and expected to persist, pressuring US revenue growth.
Fast read
Guidance and risk preview
Management expects domestic business to continue growing 100-150 basis points above the Indian pharmaceutical market growth rate.
The minimum import price on PenG and its derivatives could impact gross margins by ₹80-100 crore, partially offset by pricing actions in trade gene...
View Risks →